550 related articles for article (PubMed ID: 24928190)
1. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
3. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
[TBL] [Abstract][Full Text] [Related]
6. Drug interactions with solid tumour-targeted therapies.
Thomas-Schoemann A; Blanchet B; Bardin C; Noé G; Boudou-Rouquette P; Vidal M; Goldwasser F
Crit Rev Oncol Hematol; 2014 Jan; 89(1):179-96. PubMed ID: 24041628
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
[TBL] [Abstract][Full Text] [Related]
8. Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors.
Terada T; Noda S; Inui K
Pharmacol Ther; 2015 Aug; 152():125-34. PubMed ID: 25976912
[TBL] [Abstract][Full Text] [Related]
9. Moving towards dose individualization of tyrosine kinase inhibitors.
Klümpen HJ; Samer CF; Mathijssen RH; Schellens JH; Gurney H
Cancer Treat Rev; 2011 Jun; 37(4):251-60. PubMed ID: 20833478
[TBL] [Abstract][Full Text] [Related]
10. Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Gao B; Yeap S; Clements A; Balakrishnar B; Wong M; Gurney H
J Clin Oncol; 2012 Nov; 30(32):4017-25. PubMed ID: 22927532
[TBL] [Abstract][Full Text] [Related]
11. Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care.
Lankheet NA; Knapen LM; Schellens JH; Beijnen JH; Steeghs N; Huitema AD
Ther Drug Monit; 2014 Jun; 36(3):326-34. PubMed ID: 24305627
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma.
Henriksen JN; Andersen CU; Fristrup N
Clin Genitourin Cancer; 2024 Jun; 22(3):102064. PubMed ID: 38555681
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetic issues on cancer pharmacotherapy].
Tanigawara Y
Nihon Rinsho; 2015 Aug; 73(8):1357-63. PubMed ID: 26281690
[TBL] [Abstract][Full Text] [Related]
14. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
[TBL] [Abstract][Full Text] [Related]
15. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell A; Groenland SL; Scherf-Clavel O; van Dyk M; Huisinga W; Michelet R; Jaehde U; Steeghs N; Huitema ADR; Kloft C
Eur J Clin Pharmacol; 2021 Apr; 77(4):441-464. PubMed ID: 33165648
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma.
Liao D; Shangguan D; Yao D; Zhu Q; Cao L; Long M; Wu Y; Xiang D; Yang N
Protein Pept Lett; 2018; 25(6):528-533. PubMed ID: 29848258
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Drug Monitoring of Targeted Anticancer Protein Kinase Inhibitors in Routine Clinical Use: A Critical Review.
Cardoso E; Guidi M; Blanchet B; Schneider MP; Decosterd LA; Buclin T; Csajka C; Widmer N
Ther Drug Monit; 2020 Feb; 42(1):33-44. PubMed ID: 31479043
[TBL] [Abstract][Full Text] [Related]
19. [Personalized medicine for oral molecular-targeted anticancer drugs].
Miura M
Nihon Yakurigaku Zasshi; 2019; 153(2):73-78. PubMed ID: 30745517
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.
Oude Munnink TH; Henstra MJ; Segerink LI; Movig KL; Brummelhuis-Visser P
Clin Pharmacol Ther; 2016 Apr; 99(4):419-31. PubMed ID: 26265133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
